Hi in die Runde,
einige der Fragen lassen sich aus der Unternehmenspräsentation entnehmen:
Unterscheidung zum Wettbewerb: Andere Vertriebsstruktur geplant (schneller / günstiger)
Der weltweit erste "Selbsttest" auf Bauchspeichedrüsenkrebs wird entwickelt
Quelle: https://mainzbiomed.com/wp-content/uploads/2021/...ation-Nov_5_21.pdf
The competition’s approach...
The largest U.S. provider independently markets and distributes its product directly. All nationwide samples must come from, and be returned to, a single corporate laboratory – a time-consuming process.
Mainz BioMed intends to develop and leverage scalable dissemination through a collaborative partner program
PARTNERSHIPS:
Large lab chains incentivized to support sales & marketing efforts to physician clients & consumers.
RELATIONSHIPS:
Established regional and national labs offer existing client
relationships
(i.e.: physicians, clinics, hospitals, universities, government institutions, health organizations, etc).
PROFITABILITY:
ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance.
PROTECTION:
Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations.
ColoAlert targets lower cost than ColoGuard
ColoAlert has 3 out of 4 biomarkers identical to ColoGuard ColoGuard requires significantly larger stool samples ColoGuard is reimbursed @ about $500 in USA
MainzBioMed is currently developing proprietary genetic testingmethods for pancreatic cancer.
THE WORLD'S FIRST EARLY DETECTION PANCREATIC CANCER SCREENING TEST based on real-time PCR-based detection of biomarkers in stool samples. |
